190 filings
8-K
EVFM
Evofem Biosciences, Inc.
28 Mar 24
Regulation FD Disclosure
5:11pm
8-K
EVFM
Evofem Biosciences, Inc.
27 Mar 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
8:36am
8-K
EVFM
Evofem Biosciences, Inc.
6 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EVFM
Evofem Biosciences, Inc.
1 Feb 24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
9:05am
8-K
EVFM
Evofem Biosciences, Inc.
31 Jan 24
Entry into a Material Definitive Agreement
4:26pm
8-K
oy6zktraml8
11 Jan 24
Entry into a Material Definitive Agreement
4:53pm
8-K
4e7ngxv
26 Dec 23
Entry into a Material Definitive Agreement
5:37pm
8-K
27w4v99ip59ge287z
12 Dec 23
Entry into a Material Definitive Agreement
5:17pm
8-K
bpbf2oj so
7 Dec 23
Entry into a Material Definitive Agreement
4:05pm
8-K
iod33643ri
14 Nov 23
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
12:00am
8-K
uxq1maj
24 Oct 23
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
7:40am
8-K
o61qwoounc0cwpg151
3 Oct 23
Entry into a Material Definitive Agreement
4:07pm
8-K
yit17cux1
27 Sep 23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
8:50am
8-K
uqqlsp
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:49pm
8-K
tdy4l 2ebj
11 Sep 23
Entry into a Material Definitive Agreement
8:01am
8-K
qyhfaj8g
28 Aug 23
Regulation FD Disclosure
4:30pm
8-K
uhb7as2
14 Aug 23
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
5:25pm
8-K
1qjr 88f2ts
10 Aug 23
Entry into a Material Definitive Agreement
5:29pm
8-K
99tpfbuy5v3rdp5in
17 Jul 23
Material Modifications to Rights of Security Holders
4:05pm
8-K
5m7as 6mba4ufbt64lk
10 Jul 23
Entry into a Material Definitive Agreement
5:16pm